Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference

2 years ago

WATERTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,…

Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression

2 years ago

The application is for a novel psychedelic-based combination, of Clearmind's MEAI and SciSparc's Cannamide™ Tel Aviv, Israel / Vancouver, Canada,…

SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression

2 years ago

The application refers to a novel psychedelic-based combination of Clearmind's MEAI and SciSparc's Cannamide™ TEL AVIV, Israel, April 21, 2023 (GLOBE NEWSWIRE)…

LianBio Promotes Pascal Qian to Chief Commercial Officer

2 years ago

SHANGHAI, China and PRINCETON, N.J., April 21, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing…

EDAP Announces Major Presence at Upcoming Annual Meeting of the American Urological Association (AUA)

2 years ago

  Meeting to Showcase EDAP’s Focal One® Robotic High Intensity Focused Ultrasound (HIFU) Platform for the Management of Prostate Cancer…

Solid Biosciences to Participate in Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

2 years ago

CHARLESTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines…

Revolutionary Oxygen Treatment now available in Montreal at Les Cours Hyperbaric Center

2 years ago

Private Chamber Private Chamber Private Chamber (2) Private Chamber (2) Mono Private Chamber (Mom & Child) Mono Private Chamber (Mom…

Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting

2 years ago

SOUTH SAN FRANCISCO, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a development-stage biopharmaceutical company developing…

CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)

2 years ago

NEWARK, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and…

Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer

2 years ago

Seasoned operating executive with successful track record at late-stage biopharmaceutical companiesFARMINGTON HILLS, Mich., April 21, 2023 (GLOBE NEWSWIRE) -- Ocuphire…